Valeant Pharmaceuticals Intl Inc (VRX) Earns Outperform Rating from Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a report published on Monday morning, reports. Royal Bank Of Canada currently has a C$46.00 price target on the specialty pharmaceutical company’s stock.

Other analysts have also issued research reports about the company. TD Securities decreased their price objective on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank decreased their price objective on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of C$38.67.

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 32.41 on Monday. The firm’s market capitalization is $11.26 billion. Valeant Pharmaceuticals Intl has a one year low of $24.32 and a one year high of $240.40. The stock’s 50 day moving average price is $36.63 and its 200-day moving average price is $35.33.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Stock Target Prices

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.